Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_1
2
25%
Ph phase_2
6
75%

Phase Distribution

2

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
6(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(6)
Terminated(2)

Detailed Status

Completed6
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
85.7%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (25.0%)
Phase 26 (75.0%)

Trials by Status

completed675%
terminated113%
withdrawn113%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_2

Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma

NCT00005976
completedphase_2

Pyrazoloacridine in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT00002656
terminatedphase_1

Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma

NCT00053950
completedphase_2

Pyrazoloacridine in Treating Women With Refractory Metastatic Breast Cancer

NCT00003041
completedphase_2

Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma

NCT00003802
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT00005976Phase 2

Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma

Completed
NCT00002656Phase 2

Pyrazoloacridine in Treating Patients With Advanced Non-small Cell Lung Cancer

Completed
NCT00053950Phase 1

Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma

Terminated
NCT00003041Phase 2

Pyrazoloacridine in Treating Women With Refractory Metastatic Breast Cancer

Completed
NCT00003802Phase 2

Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma

Completed
NCT00006355Phase 1

Pyrazoloacridine Followed by Radiation Therapy in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Completed
NCT00002585Phase 2

Pyrazoloacridine in Treating Women With Metastatic Breast Cancer

Completed
NCT00003714Phase 2

Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer

Withdrawn

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8